Although inhibition of IN-LEDGF/p75 binding was initially thought to underlie the antiviral mechanism, Engelman’s work clarified that exposing HIV-1 to the drugs during virus production inhibited subsequent viral infection more potently than did treating the infected cells themselves during the early phase of HIV-1 infection when integration occurs. The gene discussed is PSIP1; the disease is HIV-1 infection.